Chief Scientific Officer and translational R&D leader with a proven track record of advancing biomedical innovations from concept through clinical validation and toward commercialization.
I am a translational scientist and executive leader focused on transforming complex biological insights into clinically meaningful solutions. I operate at the intersection of science, strategy, and execution—leading the development of novel diagnostic and therapeutic platforms from early discovery through clinical application.
As Co-Founder and Chief Scientific Officer of Isomark, I led the end-to-end development of a novel infection monitoring platform—spanning early biomarker discovery through clinical validation. My leadership experience includes building and guiding cross-functional teams across engineering, clinical research, and regulatory domains, while aligning scientific innovation with strategic and commercial objectives.
My academic background at the University of Wisconsin–Madison established a foundation in metabolomics, stable isotope biology, and translational research, with applications in infection, inflammation, and metabolic disease. I bring a combination of scientific depth and enterprise perspective—contributing not only to R&D execution, but also to funding strategy, partnerships, and organizational growth.
A track record of measurable impact across the full pipeline—from discovery science to clinical validation, regulatory strategy, capital formation, and executive leadership.
Two boardroom-caliber narratives demonstrating how scientific leadership translates into enterprise results. Click either card to expand.
As Co-Founder and Chief Scientific Officer, I led the development of a novel breath-based diagnostic platform for infection monitoring—advancing the technology from early-stage biomarker discovery through human clinical validation and toward commercialization. This effort required integrating scientific innovation, clinical strategy, regulatory planning, and organizational leadership into a unified development pathway.
Early-stage scientific discoveries often fail to translate into clinically viable products due to gaps between research, development, and real-world application. Key challenges included:
As Co-Founder and Chief Scientific Officer, I played a central role in positioning a novel diagnostic platform for strategic partnerships, investment, and potential acquisition—engaging with global leaders across medtech, diagnostics, and adjacent industries. This required translating complex science into clear clinical, commercial, and strategic value for diverse stakeholders.
Innovative technologies often struggle to gain traction with large strategic partners due to misalignment between scientific differentiation and commercial priorities. Key challenges included:
Contributed to national-level recognition of novel diagnostic technology, including acknowledgment on the U.S. Senate floor.
Outcome: Elevated awareness with investors, policymakers, and strategic stakeholders
Secured >$2.4M in NIH SBIR Phase I & II funding as PI; engaged directly with senior stakeholders including former Governor Tommy Thompson.
Outcome: Non-dilutive capital enabling de-risked platform advancement
Led discussions with Medtronic, GE Healthcare, Masimo, Zoetis, and Cargill; supported due diligence and transaction preparation.
Outcome: Platform positioned for acquisition and partnership opportunities
Designed and executed multi-center trials at UW–Madison, Duke, Washington University, and The Ohio State University with KOL endpoint committees.
Outcome: Clinically meaningful data from high-acuity patient populations
Co-invented a novel breath-based diagnostic platform; translated biomarker discovery into a clinically validated infection monitoring system with a defensible IP portfolio.
Outcome: Multiple issued U.S. patents and ongoing commercialization pathway
A career built at the intersection of academic research, startup leadership, and enterprise strategy.
A measurable record of scientific output, intellectual property creation, and competitive grant funding.
Open to executive leadership opportunities, advisory roles, and strategic partnerships in translational medicine and biomedical innovation.
Based in Wisconsin · Open to remote and on-site executive opportunities